Glenmark Pharmaceuticals reported a consolidated profit of Rs 348 crore in Q3 FY25, reversing a Rs 351 crore loss a year ago. Revenue surged 35% to Rs 3,388 crore, driven by strong growth in Europe and branded markets. The US Food and Drug Administration (USFDA) issued five observations for its Indore plant, with no data integrity concerns. Glenmark shares closed 6.28% lower at Rs 1,321.35 on BSE.
